Click here for slides on this topic


Lipoprotein

An organic molecule consisting of a mixture of protein and lipid. Most of the lipids (fat) in the blood are found in lipoprotein complexes.


The following content matched the glossary term: Lipoprotein

American Heart Association (AHA) Scientific Sessions 2012

Top

Exclusive coverage of late-breaking data from the American Heart Association Scientific Sessions, November 3-7, 2012 in Los Angeles, California are featured in this issue of OnsiteInsight®.

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 9, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 9, 2012

Results from the EASIE, EUREXA, TODAY, and Diabetes Prevention Program (DPP) trials; new data on SGLT2 inhibitors for diabetes treatment, incretins for diabetes treatment, ATP-IV guideline update, and more.

 

Pharmacist-led shared medical appointments for multiple cardiovascular risk reduction in patients with type 2 diabetes

Top

Cohen LB, Taviera TH, Khatana SA, Dooley AG, Pirraglia PA, Wu WC. Pharmacist-led shared medical appointments for multiple cardiovascular risk reduction in patients with type 2 diabetes. Diabetes Educ. 2011 Oct 21. [Epub ahead of print]. To assess whether VA MEDIC-E (Veterans Affairs Multi-disciplinary Education and Diabetes Intervention for Cardiac risk reduction— Extended for 6 months), a pharmacist-led shared medical appointments program, could improve attainment of target goals for hypertension, hyperglycemia, hyperlipidemia, and tobacco use in patients with type 2 diabetes compared to standard primary care after 6 months of intervention.

Metabolic outcomes 1 year after gastric bypass surgery in obese people with type 2 diabetes

Top

Demssie YN, Jawaheer J, Farook S, New JP, Syed AA. Metabolic outcomes 1 year after gastric bypass surgery in obese people with type 2 diabetes. Med Princ Pract. 2011 Oct 20. [Epub ahead of print]. To assess metabolic outcomes in obese people with type 2 diabetes (T2D) in the first year following gastric bypass surgery.

Effects of combination lipid therapy in type 2 diabetes mellitus

Top

ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-1574. We investigated whether combination therapy with a statin plus a fibrate, as compared with statin monotherapy, would reduce the risk of cardiovascular disease in patients with type 2 diabetes mellitus who were at high risk for cardiovascular disease.

The role of pioglitazone in modifying the atherogenic lipoprotein profile

Top

Hanefeld M. The role of pioglitazone in modifying the atherogenic lipoprotein profile. Diabetes, Obesity and Metabolism. 2009;11(8):742-756. Pioglitazone, a thiazolidinedione, has established efficacy in improving glycaemic control in patients with type 2 diabetes. Pioglitazone also improves components of the mixed dyslipidaemia profile common in these patients, as typified by raised levels of plasma triglycerides, low levels of HDL cholesterol (HDL-C) and a raised proportion of LDL cholesterol (LDL-C) occurring as the small dense subfraction.

Pioglitazone decreases postprandial accumulation of remnant lipoproteins in insulin-resistant smokers

Top

Abbasi F, Lamendola C, Leary ET, Reaven GM. Pioglitazone decreases postprandial accumulation of remnant lipoproteins in insulin-resistant smokers. Diabetes, Obesity and Metabolism. 2009;11(8):779-785. Fasting hypertriglyceridaemia has been reported to occur commonly in cigarette smokers and is thought to increase cardiovascular disease (CVD) risk in these individuals.

Glycated albumin and direct low density lipoprotein cholesterol levels in type 2 diabetes mellitus

Top

Ai M, Otokozawa S, Schaefer EJ, et al. Glycated albumin and direct low density lipoprotein cholesterol levels in type 2 diabetes mellitus. Clin Chimica Acta.. 2009;406(1-2):71-74. Diabetes mellitus is a major risk factor for coronary heart disease (CHD), renal failure, retinopathy, and neuropathy. Lowering glycosylated hemoglobin (HbA1c) as well as low-density lipoprotein-cholesterol (LDL-C) has been associated with a decreased risk of these complications.

Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus

Top

Galvano F, Li Volti G, Malaguarnera M, et al. Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. Expert Opin Pharmacother. 2009;10(12):1875-1882. The aim of the present study was to compare the effects of simvastatin and L-carnitine coadministration versus simvastatin monotherapy on lipid profile, lipoprotein(a) (Lp(a)) and apoprotein(a) (Apo(a)) levels in type II diabetic patients.

Long-term pioglitazone therapy improves arterial stiffness in patients with type 2 diabetes mellitus

Top

Harashima K, Hayashi J, Miwa T, Tsunoda T. Long-term pioglitazone therapy improves arterial stiffness in patients with type 2 diabetes mellitus. Metabolism. 2009;58(6):739-745. Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, not only improves insulin resistance and glycemic control, but may also have additional beneficial vascular effects in patients with type 2 diabetes mellitus.

1 2 3 4 5 6 7 8 9 Next 

Slide Library Results

Search Results for: Lipoprotein Slides Found: 31
ACP Guidelines on Management of Dyslipidemia in Type 2 Diabetes
Metabolic and Vascular Actions of PPAR-alpha and PPAR-gamma Agonists
Pioglitazone Reduces VLDL-TG Levels by Increasing LPL-Mediated Lipolysis
Non–HDL-C as a Predictor of Risk for CHD in Diabetes
Drug Nonadherence Is Associated With Adverse Clinical Outcomes in Diabetes
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Lipids
GLAI: Comparison of TZDs on Lipoprotein Subclass Particle Size
JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Rationale
JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Participant Profile
CANTATA-D2: Design
CANTATA-D2: Effect of Canagliflozin Vs Sitagliptin on Lipid Values at 52 Weeks
CANTATA-M: Effect of Canagliflozin Vs Placebo on Lipid Values at 26 Weeks
CANTATA-M: Design
ESH/ESC Hypertension Guidelines: Individuals at Higher CV Risk
Canola Oil Diet Study Glycemia A1C Type 2 Diabetes | NDEI
VA BEACH DIET Study: Impact of Diet on CVD Risk | NDEI
CVD Treatment Statin ADA Type 1 Diabetes Guidelines | NDEI
JUPITER Secondary Analysis Assesses Statin Use & Diabetes Risk | NDEI
JUPITER High-Intensity Rosuvastatin & Lipoprotein Particles | NDEI
JUPITER Effect of High-Intensity Rosuvastatin on Lipoproteins Diabetes | NDEI
JUPITER Rosuvastatin & Incident Type 2 Diabetes | NDEI
JUPITER Insulin Resistance Associated With Risk Factors | NDEI
JUPITER Incident Diabetes Associated With More Risk Factors Rosuvastatin | NDEI
GAUSS-3 Evolocumab Effects on Lipoproteins in Statin-Intolerant Patients | NDEI
HOPE-3 LDL & Lipoprotein Reductions With Rosuvastatin Vs Placebo | NDEI
Lipoprotein Screening in Children & Adolescents NLA Cholesterol Guidelines | CCMD
NLA Cholesterol Guidelines Lipid Screening Recommendations PPT | CCMD
NLA Cholesterol Guidelines Moderate ASCVD Risk PPT | CCMD
NLA Cholesterol Guidelines Low ASCVD Risk PPT | CCMD
NLA Cholesterol Guidelines ASCVD Risk Refinement PPT | CCMD
FH Treatment LDL-Apheresis NLA Cholesterol Guidelines PPT | CCMD